Substance-Related Disorders
Disorders related to substance use or abuse.
Subtype terms (15)
More specific conditions that are subtypes of Substance-Related Disorders in the MeSH hierarchy.
- Alcohol-Related Disorders
37 drugs (28 approved, 9 experimental)
- Amphetamine-Related Disorders
30 drugs (24 approved, 6 experimental)
- Cocaine-Related Disorders
156 drugs (121 approved, 35 experimental)
- Drug Misuse
48 drugs (44 approved, 4 experimental)
- Inhalant Abuse
- Marijuana Abuse
49 drugs (40 approved, 9 experimental)
- Marijuana Use
8 drugs (5 approved, 3 experimental)
- Narcotic-Related Disorders
10 drugs approved
- Neonatal Abstinence Syndrome
15 drugs (8 approved, 7 experimental)
- Phencyclidine Abuse
- Psychoses, Substance-Induced
2 drugs approved
- Substance Abuse, Intravenous
10 drugs (9 approved, 1 experimental)
- Substance Abuse, Oral
50 drugs (41 approved, 9 experimental)
- Substance Withdrawal Syndrome
62 drugs (49 approved, 13 experimental)
- Tobacco Use Disorder
93 drugs (63 approved, 30 experimental)
Drugs by status
Approved for this indication (12)
Phase 4 trials (34)
- brexpiprazole
- oxytocin
- acetylcysteine
- clozapine
- methylphenidate
- valproic acid
- suvorexant
- elbasvir
- naltrexone
- tenofovir
- carbamazepine
- fluoxetine
- olanzapine
- acetaminophen
- nicotine
- ribavirin
- risperidone
- oritavancin
- emtricitabine
- trazodone
- creatine
- bupropion
- atomoxetine
- aripiprazole
- varenicline
- naloxone
- quetiapine
- pregabalin
- grazoprevir
- desipramine
- +4 more
Phase 3 trials (8)
Phase 2 trials (37)
- nitrous oxide
- flupentixol
- carisbamate
- ketamine
- cycloserine
- isoflurane
- sevoflurane
- sertraline
- gsk598809
- guanfacine
- icosapent ethyl
- lorazepam
- cabergoline
- nefazodone
- pergolide
- flumazenil
- pro-docosapentaenoic acid
- propranolol
- ramelteon
- semaglutide
- rotigotine
- triazolam
- carvedilol
- fentanyl
- midazolam
- oxygen
- modafinil
- mirtazapine
- psilocybin
- levomethadyl acetate
- +7 more
Phase 1 trials (54)
- fingolimod
- efavirenz
- pitolisant
- samidorphan
- phentermine
- lorcaserin
- candesartan
- cebranopadol
- dexmecamylamine
- diltiazem
- disulfiram
- duloxetine
- nifedipine
- ethanol
- escitalopram
- ritonavir
- ibudilast
- amantadine
- esketamine
- istradefylline
- lobeline
- lofexidine
- dronabinol
- opipramol
- pindolol
- atazanavir
- reboxetine
- tizanidine
- remimazolam
- immune globulin (human)
- +24 more
Other trials (26)
Organizations
Organization Involved with Phase 4 Indications (67)
- Abbott
- Bristol-Myers Squibb
- Gilead Sciences
- AstraZeneca
- Merck
- Pfizer
- Novartis
- Alkermes
- GlaxoSmithKline
- Indivior Inc.
- Member Companies of the Opioid PMR Consortium
- Friends Research Institute, Inc.
- Otsuka
- The EMMES Corporation
- National Institutes of Health (NIH)
- National Institute on Alcohol Abuse and Alcoholism (NIAAA)
- National Institute on Drug Abuse (NIDA)
- University of Pittsburgh
- Augusta University
- Harvard University
- Dartmouth University
- Duke University
- Federal University of Rio Grande do Sul
- Fenway Community Health
- George Mason University
- University of Washington
- Hanoi Medical University
- Howard University
- Johns Hopkins University
- Lund University
- +37 more
Organization Involved with Phase 3 Indications (20)
- Braeburn Pharmaceuticals
- French National Agency for Research on AIDS and Viral Hepatitis
- National Institute of Mental Health (NIMH)
- University of Pennsylvania
- Case Western Reserve University
- Emory University
- Hoosier Cancer Research Network
- Monash University
- National Cheng Kung University
- Norwegian University of Science and Technology
- University of Oslo
- University of California, Los Angeles
- University of Cincinnati
- Georgia Institute of Technology
- City University of New York
- Burnet Institute
- Pennsylvania State University
- University of New South Wales
- Brain & Behavior Research Foundation
- Lade Addiction Treatment Center
Organization Involved with Phase 2 Indications (38)
- New River Pharmaceuticals
- Takeda
- Eli Lilly
- Cassava Sciences
- Public Health Foundation Enterprises, Inc.
- Research Foundation for Mental Hygiene, Inc.
- National Heart, Lung, and Blood Institute (NHLBI)
- Hurd,Yasmin, Ph.D.
- Instituto Nacional de Psiquiatría Dr. Ramón de la Fuente
- Baylor University
- Boston University
- Henry Ford Health System
- McGill University
- Melbourne Health
- Multidisciplinary Association for Psychedelic Studies
- Universidad Autonoma de Madrid
- University of Kentucky
- University of Maryland
- University of Melbourne
- University of Tehran
- Wayne State University
- University of Vermont
- University of British Columbia
- University of Chicago
- Vancouver Coastal Health
- Canadian Research Initiative in Substance Misuse
- Department of Defense
- GW Research
- US WorldMeds
- Rovira i Virgili University
- +8 more
Organization Involved with Phase 1 Indications (38)
- Cephalon
- Grunenthal
- MediciNova
- Astellas
- Arena Pharmaceuticals
- Bioprojet
- INC Research
- Kyowa Hakko Kirin
- Paion UK Ltd.
- National Center for Complementary and Integrative Health (NCCIH)
- National Institute of Neurological Disorders and Stroke (NINDS)
- British University In Egypt
- Brown University
- Cairo University
- Medical College of Wisconsin
- University of Milan
- University of Bern
- University of Basel
- Bar Ilan University
- Clinilabs
- Karolinska Institute
- Pharmaceutical Research Associates, Inc. (PRA)
- University of Lyon
- University of Wisconsin
- Insys Therapeutics Inc
- Partnership for Clean Competition
- Heffter Research Institute
- Foundation of Hope, North Carolina
- County of Stockholm
- Johnson and Johnson
- +8 more
Organization Involved with Other Experimental Indications (16)
- American Society Of Thermalism And Climatology Inc
- National Institute of General Medical Sciences (NIGMS)
- United States Army
- Aarhus University
- Florida International University
- Norwegian School of Sport Sciences
- Stanford University
- University of South Florida
- Virginia Commonwealth University
- University of California, Berkeley
- Artemis Institute for Clinical Research
- University of Colorado
- American Academy of Child Adolescent Psychiatry.
- MedicaSafe, Inc.
- Medical Home Development Group
- Geneus Health